catalym
Posted by catalym
September 26, 2022
September 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...

Read More
catalym
Posted by catalym
September 10, 2022
September 10, 2022

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...

Read More
catalym
Posted by catalym
September 5, 2022
catalym
Posted by catalym
March 1, 2022
March 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

ESMO 2022

September 9-13, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

22nd Annual Biotech forum

September 21-22, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

BIO-Europe 2022

October 24-26

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

SITC 2022

November 8-12, 2022

Read More
catalym
Posted by catalym
November 15, 2021
November 15, 2021

Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment

Markus Haake, Tina Schäfer, Beatrice Haack, Neha Vashist, Sabrina Genßler, Patrick Harter,...

Read More
catalym
Posted by catalym
November 15, 2021
November 15, 2021

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz,...

Read More